Related Experiment Video
Updated: May 7, 2026
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Effect of statins on platelet function in patients with hyperlipidemia
Joanna Sikora1, Barbara Kostka, Iwona Marczyk
1Department of Pharmaceutical Chemistry and Drug Analyses, Medical University of Lodz, Poland.
Insights
Statins reduce adenosine diphosphate (ADP)-induced platelet aggregation in hyperlipidemic patients, independent of cholesterol levels. This study shows statins improve hemorheological conditions by affecting platelet activation.
Area of Science:
- Cardiology
- Pharmacology
- Hematology
Background:
- Statins are primarily known for cholesterol reduction in cardiovascular disease.
- Statin effects may extend beyond lipid lowering, influencing hemorheological conditions and endothelial function.
- This study investigates statin impact on platelet function in hyperlipidemia.
Purpose of the Study:
- To evaluate how statin treatment affects platelet adhesion and aggregation in patients with type II hyperlipidemia.
- To determine if statin's benefits are solely due to cholesterol reduction or also involve direct effects on platelet activity.
Main Methods:
- 70 participants (50 hyperlipidemic patients, 20 healthy controls) were included.
- An 8-week treatment regimen with atorvastatin, simvastatin, or pravastatin was administered.
- Platelet adhesion and aggregation (spontaneous, ADP-, collagen-, or ristocetin-induced) were assessed before and after treatment.
Main Results:
- All statins significantly decreased adenosine diphosphate (ADP)-induced platelet aggregation.
- No significant changes were observed in spontaneous or ADP-activated platelet adhesion to fibrinogen.
- Collagen- or ristocetin-induced platelet aggregation and adhesion remained unaffected by statin therapy.
Conclusions:
- Statin therapy positively modulates ADP-induced platelet aggregation in hyperlipidemic patients.
- Statins do not influence spontaneous platelet adhesion or aggregation induced by collagen or ristocetin.
- These findings suggest statins have hemorheological benefits partly independent of their lipid-lowering effects.
Introduction:
It is generally assumed that cholesterol reduction by statins is the predominant therapeutic result underlying their beneficial effects in cardiovascular disease. However, the action of statins may be partially independent of their effects on plasma cholesterol levels, as they combine lipid lowering with positive effects on hemorheological conditions and endothelial function. We evaluated the impact of statin treatment on platelet adhesion to fibrinogen (spontaneous and ADP-activated), along with ADP, collagen or ristocetin-induced aggregation in type II hyperlipidemic patients.
Material And Methods:
The study group included 70 persons: 50 patients affected by type II hyperlipidemia without concomitant diseases and 20 healthy volunteers. The effects of 8-week statin treatment (atorvastatin 10 mg/day, simvastatin 20 mg/day, or pravastatin 20 mg/day) on platelet activation were evaluated.
Results:
Regardless of the type of statin, a significant decrease in ADP-induced platelet aggregation was observed: for atorvastatin 50.6 ±12.8% vs. 41.1 ±15.8% (p < 0.05), for simvastatin 57.2 ±18.0% vs. 44.7 ±22.1% (p = 0.05), and for pravastatin 55.8 ±19.5% vs. 38.8 ±23.3% (p < 0.05). There was no significant effect of statins on collagen or ristocetin-induced platelet aggregation and adhesion.
Conclusions:
Therapy with statins beneficially modifies ADP-induced platelet aggregation in patients with hyperlipidemia and does not affect spontaneous or ADP-induced platelet adhesion to fibrinogen and platelet aggregation induced by collagen or ristocetin.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Atherosclerosis III: Management
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:18Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...